European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?
Anaemia
Bevacizumab
Digestive bleeding
Hereditary haemorrhagic telangiectasia
Iron deficiency
Nosebleeds
Journal
European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
30
11
2021
revised:
09
06
2022
accepted:
20
07
2022
pubmed:
9
8
2022
medline:
16
9
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
Hereditary haemorrhagic telangiectasia (HHT) is a rare vascular multisystemic disease that leads to epistaxis, anaemia due to blood loss, and arteriovenous malformations (AVMs) in organs such as the lungs, liver and brain. HHT prevalence is estimated at 1/6000, i.e. around 85,000 European citizens, and is served by the European Reference Network for Rare Multisystemic Vascular Diseases (VASCERN). HHT treatments depend on clinical manifestations, and span multiple different medical, surgical and interventional disciplines. Separate to local treatments in the nose, in severe settings, intravenous bevacizumab has been proposed as treatment option, and the purpose of the current article is to assess the use of intravenous bevacizumab in patients with HHT in 2022 according to available data.
Identifiants
pubmed: 35940549
pii: S1769-7212(22)00156-2
doi: 10.1016/j.ejmg.2022.104575
pii:
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104575Investigateurs
Claudia Crocione
(C)
Ria Blom
(R)
Luisa Maria Botella
(LM)
Fernando Brocca
(F)
Caroline Coxall
(C)
Karen T Druckman
(KT)
Didier Erasme
(D)
Paolo Federici
(P)
Christina Grabowski
(C)
Mildred Lundgren
(M)
Tone Søderman
(T)
Dara Woods
(D)
Informations de copyright
Copyright © 2022 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Authors have no competing interest to declare. The institution (Hospices Civils de Lyon) has received the drug, bevacizumab from Roche company for Metafore study (2009) and nintedanib from Boerhinger-Ingelheim for Epicure study (2020).